Wait-and-scan strategy feasible for head, neck paraganglioma

July 17, 2017

(HealthDay)—A wait-and-scan strategy seems to be feasible for patients with head and neck paraganglioma (PGL), according to a study published online July 10 in Head & Neck.

Thijs T.G. Jansen, from the Radboud University Medical Center in Nijmegen, Netherlands, and colleagues conducted a involving patients with head and neck PGL. The authors measured tumor growth in axial plane diameter and volume during a wait-and-scan period.

The researchers found that 44 percent of 59 jugulotympanic tumors, 71 carotid body tumors, and 29 vagal body tumors were growing (median growth rates, 0.41, 1.6, and 1.6 mm/year, respectively). There was a significant correlation for growth with age at presentation (odds ratio, 0.974; P < 0.05). Twenty complications were induced by 17 tumors; six of these were growing, and the rates were higher than in non-complication-inducing tumors (P = 0.016).

"The results of this study illustrate that a wait-and-scan policy is a feasible treatment option in cases for head and PGL, as it potentially prevents treatment-induced morbidity in the majority of patients, including those presenting larger tumors," the authors write. "Our results also suggest that radiological follow-up is not an optimal management strategy, because a large group of tumors were found not to grow, although they did elicit complications, in the main, years after the initial diagnosis."

Explore further: Report describes primary clear cell sarcoma of head, neck

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Report describes primary clear cell sarcoma of head, neck

June 13, 2016
(HealthDay)—Three cases of primary clear cell sarcoma of the head and neck have been described in three male patients, according to a review published online June 6 in the Journal of Cutaneous Pathology.

Reduced cancer-independent life expectancy in head, neck cancer

June 27, 2017
(HealthDay)—Patients with head and neck cancer have reduced life expectancy, independent of cancer, according to a study published online June 22 in Head & Neck.

Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

April 3, 2017
New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer ...

Smoking, T4 tumors up distant mets in HPV+ oropharyngeal CA

February 15, 2017
(HealthDay)—For patients with human papillomavirus (HPV)-positive oropharyngeal cancer, active smokers and those with T4 tumors have increased rates of distant metastases, according to a study published online Feb. 11 in ...

More side effects with CRT plus metformin in head, neck cancer

May 7, 2017
(HealthDay)—Patients with advanced head and neck cancer undergoing chemoradiotherapy (CRT) and receiving metformin experience more side effects than patients not on metformin, according to research published online April ...

Recommended for you

Breast cancer genes a real risk for men, too

April 26, 2018
(HealthDay)—Few American men are screened for gene mutations that can greatly increase their risk of breast and other types of cancers, a new study reveals.

Metastatic cancer gorges on fructose in the liver

April 26, 2018
Biomedical engineers at Duke University have demonstrated that metastatic cancer cells can reprogram their metabolism to thrive in new organs. Specifically, the research shows that cells originating from colorectal cancer ...

Blood cancer precursor found in 9/11 firefighters

April 26, 2018
A study in today's issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead ...

Largest-ever study of thyroid cancer genetics finds new mutations, suggests immunotherapy

April 26, 2018
University of Colorado Cancer Center researchers recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid ...

Molecular culprit behind virus-mediated chronic inflammation and cancers identified

April 26, 2018
Within cells infected by Kaposi sarcoma herpesvirus (KSHV), the human protein CADM1 interacts with viral proteins to promote chronic inflammation, which plays a major role in the development of cancers caused by KSHV. Richard ...

PARP-1 may be key to effectiveness of PARP inhibitors, and now researchers can image it

April 26, 2018
Penn Medicine researchers have used CRISPR/Cas9 gene editing technology to isolate a key genetic feature that could cause resistance to PARP inhibitors in patients with ovarian cancer—and they've also proven they have a ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.